Intrinsic Value

The intrinsic value of Fagron NV (FAGR) under the Base Case is EUR per share. Compared with the current market price of 24.65 EUR, the stock appears .

The intrinsic value is calculated using valuation multiples.

Do our valuations actually work? See backtest results .

FAGR Intrinsic Value

What one share is worth in the bear, base and bull cases.

Create a free account · No card needed

Do our valuations actually work? See backtest results .

Intrinsic value for the past 5 years is hidden
Alert me when FAGR is below its intrinsic value
Today Hidden ·
Alternatives to FAGR

Fundamental Analysis

What Fagron Does

Health Care

Fagron NV is a pharmaceutical company focused on compounding, which means making customized medicines for patients whose needs are not met by standard mass-market drugs. It sells raw materials, ready-to-use ingredients, compounding equipment, and prepared formulations that pharmacies, hospital pharmacies, and compounding centers use to make those medicines.

Headquarters
Belgium BE
Employees
4 193
IPO date
Oct 5, 2007
Read the full company overview
View Company Overview

Fagron has no economic moat

No Moat Narrow Wide

Fagron NV lacks an economic moat, leaving it vulnerable to competitive pressures and market challenges.

Read the full moat analysis
Financials

Balance Sheet

Efficiency

Wall St Price Targets

Shareholder Returns

Competitive Landscape

Recent Events

Past 12 months

Continue FAGR Research

Decided on Fagron? Get an email when FAGR reaches the price you’d buy at. Free with an account.

Other Fagron listings

What is the Intrinsic Value of one FAGR stock?

The intrinsic value for Fagron NV (FAGR) under the Base Case is EUR.

Is FAGR stock undervalued or overvalued?

Compared with the current market price of 24.65 EUR, the stock appears .

How reliable are our estimates? See how past valuations played out
Back to Top